Search Results

Avanzanite Bioscience B.V. announced that it has signed an exclusive distribution agreement with Paris-based specialty pharmaceutical company Advicenne for a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis.

Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe,

Advicenne is pleased to announce that it has signed an exclusive distribution agreement with FrostPharma AB, a Swedish pharmaceutical company, for the commercialization of Sibnayal™ in the Nordic region.

Advicenne (Euronext: ADVIC), announces is has received a positive opinion from the French Transparency Commission (HAS) with its lead asset, SibnayalTM eligible for reimbursement with a Moderate Level SMR (Medical Rendered Service) and a Level IV ASMR (Medical Rendered Service Improvement).

Advicenne, a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, provides an update on its activities following its Annual General Meeting, which was held virtually on June 14, 2021.

Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces US Food and Drug Administration (FDA) acceptance of the amended protocol of the Company’s US-based Phase III pivotal trial of ADV7103 (Sibnayal™) for the treatment of primary distal renal tubular acidosis (dRTA).

Advicenne (Paris:ADVIC) (Euronext: ADVIC), specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces today that it has received authorization from the Belgian health authority (FAMHP) to begin a pivotal Phase II/III CORAL clinical trial in cystinuria with its flagship drug candidate, ADV7103. The French pharmaceutical company also assesses its financial visibility at the close of 2018.

Advicenne, a pharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces its financial results for the full year ended December 31, 2018.

Advicenne today announced that the management of Advicenne will host a conference call on Wednesday September 12, 2018 at 6:00 pm (CEST) to comment on the latest positive developments of its product portfolio.

Advicenne (Paris:ADVIC), a French company specializing in the development of therapeutic products for adults and children for the treatment of orphan renal and neurological diseases, today published its first-half financial results as of June 30, 2018 and confirms its operating outlook for 2018.